Scholars@Duke
Aman Opneja

Aman Opneja

Assistant Professor of Medicine
Medicine, Medical Oncology

Scholarly Works - Conferences

Symbiotic-GI-03: A randomized, double-blind, phase 3 study of first-line PF-08634404, a PD-1/VEGF bispecific antibody, in combination with mFOLFOX6 in patients with metastatic colorectal cancer (mCRC).

Conference Journal of Clinical Oncology · June 1, 2026 TPS3675Background: Multi-agent chemotherapy regimens (eg, mFOLFOX6) ± anti-vascular e ... Full text Cite

Abstract CT184: Preliminary results of first-line botensilimab (BOT) and balstilimab (BAL) optimization in microsatellite stable colorectal cancer (MSS CRC) without liver, bone, or brain metastasis (BBOpCo)

Conference Cancer Research · April 17, 2026 AbstractPatients (pts) with metastatic (met) MSS CRC are treated with sequential lines of chemotherapy (chemo), but most experience progression and prolonged toxicities during their disease course. BOT is ... Full text Cite

Abstract CT073: FiREBOLT: A phase 1 study evaluating radioligand therapy with LY4337713 in adults with select FAP+ solid tumors (Trial in progress)

Conference Cancer Research · April 17, 2026 AbstractBackground:Fibroblast activation protein (FAP) is a transmembrane glycoprotein highly expressed on cancer-associated fi ... Full text Cite

Immune checkpoint blockade in locally advanced rectal cancer with deficient mismatch repair (dMMR): Retrospective multicenter experience.

Conference Journal of Clinical Oncology · June 2025 e15628Background: Total neoadjuvant therapy (TNT) with cytotoxic chemotherapy and chemoradiation followed by surgical resecti ... Full text Cite

Outcomes in bone predominant (BP) urothelial carcinoma (UC).

Conference Journal of Clinical Oncology · February 20, 2018 441 Background: The clinical phenotype of BP UC includes those patients (pts) with at least as many or more bone lesions than non-bone lesions. UC molecular subtypes that may correlate with prognosis have been defined. Better und ... Full text Cite